高级检索
    揭光灵, 牛晓敏. Orient-31模式讨论：免疫治疗在驱动基因阳性的晚期NSCLC靶向耐药后的探索[J]. 循证医学, 2024, 24(3): 138-141. DOI: 10.12019/j.issn.1671-5144.202402008
    引用本文: 揭光灵, 牛晓敏. Orient-31模式讨论：免疫治疗在驱动基因阳性的晚期NSCLC靶向耐药后的探索[J]. 循证医学, 2024, 24(3): 138-141. DOI: 10.12019/j.issn.1671-5144.202402008
    shu
    JIE Guang-ling, NIU Xiao-min. Orient-31 Model Discussion: Immunotherapy can Be Used After Drug Resistance of Advanced NSCLC With Oncogenic Driver Mutation[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 138-141. DOI: 10.12019/j.issn.1671-5144.202402008
    Citation: JIE Guang-ling, NIU Xiao-min. Orient-31 Model Discussion: Immunotherapy can Be Used After Drug Resistance of Advanced NSCLC With Oncogenic Driver Mutation[J]. Journal of Evidence-Based Medicine, 2024, 24(3): 138-141. DOI: 10.12019/j.issn.1671-5144.202402008
    shu

    Orient-31模式讨论：免疫治疗在驱动基因阳性的晚期NSCLC靶向耐药后的探索

    Orient-31 Model Discussion: Immunotherapy can Be Used After Drug Resistance of Advanced NSCLC With Oncogenic Driver Mutation

      摘要
      • HTML全文
      • 参考文献(30)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回